GTCR, a leading private equity firm, announces that it has closed the previously announced acquisition of Zentiva (the “Company”), a leading European generics pharmaceutical company, from Advent, a leading global private equity investor. Zentiva is focused on the development, manufacturing and supply of generic, branded specialty and over-the-counter medicines and products, serving more than 100 million people across over 40 countries. The Company is supported by established R&D capabilities and a deep commitment to clinical excellence and product quality across its portfolio.
Read the full article: GTCR Completes Acquisition of Zentiva, a Leading European Generics Pharmaceutical Company //
Source: https://www.prnewswire.com/news-releases/gtcr-completes-acquisition-of-zentiva-a-leading-european-generics-pharmaceutical-company-302737491.html